<DOC>
	<DOC>NCT00316225</DOC>
	<brief_summary>This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.</brief_summary>
	<brief_title>Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis of locally advanced or metastatic (Stage III or IV at entry) nonsmall cell lung cancer (NSCLC) or mesothelioma Presence of thirdspace fluid (fluid around the lungs or abdomen). Eastern Cooperative Oncology Group Performance Status of 0 or 1. Prior anticancer treatment (except radiation) must be completed at least 3 weeks prior to study enrollment, and the patient must have recovered from the sharp toxic effects the anticancer treatment. Estimated life expectancy of at least 8 weeks. Have received treatment within the last 30 days with a drug that was not a marketed product. Active infection that, in the opinion of the investigator, would not allow the patient to tolerate therapy. Pregnancy. Breastfeeding. Significant weight loss (that is, greater than or equal to 10% of body weight) over the 6 weeks before study entry. Brain metastases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>